Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GRCL Price/Volume Stats
| Current price | $10.25 | 52-week high | $10.44 |
| Prev. close | $10.24 | 52-week low | $1.40 |
| Day low | $10.17 | Volume | 6,417,100 |
| Day high | $10.28 | Avg. volume | 1,315,803 |
| 50-day MA | $9.13 | Dividend yield | N/A |
| 200-day MA | $5.01 | Market Cap | 744.95M |
GRCL Stock Price Chart Interactive Chart >
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Latest GRCL News From Around the Web
Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Gracell downgrade, Fusion upgrade: Wall Street's top analyst callsGracell downgrade, Fusion upgrade: Wall Street's top analyst calls |
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 BillionAstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion. |
These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and MoreRayzeBio surges after reaching an agreement to be acquired by Bristol Myers Squibb for $62.50 a share in cash, while Shanghai-based Gracell Biotechnologies is being bought by AstraZeneca in a deal valued at up to $1.2 billion. |
US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in viewU.S. stocks extended their rally on Tuesday, kicking off the final week of 2023 with expectations that the Federal Reserve will begin cutting interest rates as soon as March. All three major U.S. stock indexes rose in light trading a day after the Christmas holiday, with the S&P 500 touching its highest intraday level since January 2022. On Friday, the three indexes notched their eighth straight weekly gains - their longest weekly winning streaks in years - as economic data indicated inflation is easing down closer to the Fed's average annual 2% target. |
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy GoalsAstraZeneca announced Tuesday it would acquire Gracell Biotechnologies in a deal valued at up to $1.2 billion. Gracell is a Chinese biopharmaceutical company that focuses on cancer drug development. AstraZeneca said in a press release that it plans on buying the company to further its cell therapy ambitions. |
GRCL Price Returns
| 1-mo | N/A |
| 3-mo | 1.89% |
| 6-mo | 218.32% |
| 1-year | 569.93% |
| 3-year | -17.34% |
| 5-year | N/A |
| YTD | 2.09% |
| 2023 | 336.52% |
| 2022 | -61.92% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...